Carlo Rizzuto is a PhD virologist turned venture capitalist at Versant Ventures who discovered and championed the emerging field of epitranscriptomics, helping recognize its drug-development potential early and backing Gotham Therapeutics as one of the first VCs in this RNA-modification space. Beyond investing, he frequently serves as acting CEO or Chief Business Officer at portfolio companies during their formation, taking a hands-on company-building approach while specializing in creating first-wave companies around cutting-edge biology platforms before others enter the field. Carlo Rizzuto is a PhD virologist turned venture capitalist at Versant Ventures who discovered and championed the emerging field of epitranscriptomics, helping recognize its drug-development potential early and backing Gotham Therapeutics as one of the first VCs in this RNA-modification space. Beyond investing, he frequently serves as acting CEO or Chief Business Officer at portfolio companies during their formation, taking a hands-on company-building approach while specializing in creating first-wave companies around cutting-edge biology platforms before others enter the field.